Document Detail

Atrial natriuretic peptide protects against ischemia-reperfusion injury in rabbit hearts in vivo.
MedLine Citation:
PMID:  18319356     Owner:  NLM     Status:  MEDLINE    
The aim of this study is to investigate whether atrial natriuretic peptide can mimic preconditioning to protect ischemia or reperfusion injury in rabbit hearts. New Zealand white rabbits were randomized into 3 groups: (1) Controls. Hearts received a 60 minute-occlusion of the left anterior descending artery, followed by a 180 minute-reperfusion. (2) Preconditioning. Two 5-minute periods of ischemia separated by a 10-minute reperfusion, followed by a 60-minute ischemia and a 180-minute reperfusion. (3) Atrial natriuretic peptide treatment. Bolus injection of exogenous atrial natriuretic peptide (2.5 microg/kg) given intravenously at 15 minutes prior to 60 minute-ischemia followed by a 180-minute reperfusion. Myocardial necrotic area and area at risk of necrosis were determined by triphenyltetrazolium chloride staining. Ratio of necrotic area to area at risk was 49.95% +/- 1.15%, 7.95% +/- 0.33%, and 8.36% +/- 0.61% in the controls, preconditioning group, and atrial natriuretic peptide group, respectively. Both preconditioning and atrial natriuretic peptide significantly reduced the size of infarct caused by ischemia (preconditioning vs controls, P < .05; atrial natriuretic peptide vs controls, P < .05). Atrial natriuretic peptide can mimic ischemic preconditioning to protect rabbit hearts from prolonged ischemia and reperfusion injury. It may be involved in the cardioprotective mechanisms of preconditioning.
Wayne W Zhang; Nahidh W Hasaniya; Shyamal Premaratne; J Judson McNamara
Related Documents :
8853316 - Preconditioning prevents chronic reperfusion-induced coronary endothelial dysfunction i...
12871686 - Evidence of pharmacologic preconditioning during ptca by intravenous pretreatment with ...
16474186 - The role of no in ischemia/reperfusion injury in isolated rat heart.
15556966 - Preconditioning with sevoflurane decreases pecam-1 expression and improves one-year car...
9096926 - Anabolic steroid use as the possible precipitant of dilated cardiomyopathy.
20839996 - Clinical proof of practicability for an ecg device without any conductive contact.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't     Date:  2008-03-04
Journal Detail:
Title:  Vascular and endovascular surgery     Volume:  42     ISSN:  1538-5744     ISO Abbreviation:  Vasc Endovascular Surg     Publication Date:    2008 Jun-Jul
Date Detail:
Created Date:  2008-07-31     Completed Date:  2008-10-10     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101136421     Medline TA:  Vasc Endovascular Surg     Country:  United States    
Other Details:
Languages:  eng     Pagination:  263-7     Citation Subset:  IM    
Department of Surgery, School of Medicine, Loma Linda University, 11175 Campus Street, Loma Linda, CA 92354, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Atrial Natriuretic Factor / administration & dosage,  metabolism*
Disease Models, Animal
Injections, Intravenous
Ischemic Preconditioning, Myocardial*
Myocardial Infarction / metabolism,  pathology,  prevention & control*
Myocardial Reperfusion Injury / metabolism,  pathology,  prevention & control*
Myocardium / metabolism*,  pathology
Time Factors
Reg. No./Substance:
85637-73-6/Atrial Natriuretic Factor

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Local versus systemic mechanisms underlying supervised exercise training for intermittent claudicati...
Next Document:  The uraemic retention solute para-hydroxy-hippuric acid attenuates apoptosis of polymorphonuclear le...